Wockhardt shares moved higher by 19 per cent, to ₹1,472.70 on the National Stock Exchange (NSE) in Monday’s intraday trade, amid heavy volumes after the company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic ‘Zaynich’.
